Optiver Holding B.V. Boosts Holdings in Abivax SA Sponsored ADR $ABVX

Optiver Holding B.V. raised its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 985.6% in the 1st quarter, Holdings Channel.com reports. The fund owned 4,538 shares of the company’s stock after acquiring an additional 4,120 shares during the quarter. Optiver Holding B.V.’s holdings in Abivax were worth $505,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. GHP Investment Advisors Inc. increased its position in shares of Abivax by 155.6% during the first quarter. GHP Investment Advisors Inc. now owns 230 shares of the company’s stock worth $26,000 after purchasing an additional 140 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Abivax by 661.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 396 shares of the company’s stock worth $53,000 after purchasing an additional 344 shares in the last quarter. WPG Advisers LLC grew its stake in Abivax by 125.9% during the 4th quarter. WPG Advisers LLC now owns 454 shares of the company’s stock worth $61,000 after buying an additional 253 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new position in Abivax during the 4th quarter valued at about $61,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ABVX has been the subject of a number of research analyst reports. Truist Financial increased their price target on Abivax from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Wolfe Research set a $136.00 price objective on shares of Abivax in a report on Wednesday, June 3rd. Citizens Jmp reaffirmed a “market outperform” rating and issued a $187.00 price objective on shares of Abivax in a research report on Wednesday, July 1st. HC Wainwright reiterated a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Finally, Jefferies Financial Group upgraded shares of Abivax from a “hold” rating to a “buy” rating and lifted their target price for the stock from $108.00 to $158.00 in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $156.50.

Abivax Price Performance

NASDAQ:ABVX opened at $124.92 on Friday. The firm has a market capitalization of $10.90 billion, a P/E ratio of -23.98 and a beta of 0.87. Abivax SA Sponsored ADR has a 1-year low of $67.09 and a 1-year high of $148.83. The company’s fifty day moving average price is $118.54 and its 200-day moving average price is $118.41.

Abivax (NASDAQ:ABVX) last issued its earnings results on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.23. The business had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Equities analysts anticipate that Abivax SA Sponsored ADR will post -3.22 EPS for the current fiscal year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.